A disappointing earnings report has sent shares lower but odds are the stock will regain its magic.
Second-quarter results highlight Exxon's problems, though longer term the energy giant should recover.
Why the long-awaited Microsoft-Yahoo search partnership won't hurt Google.
The supermarket operator cut its outlook, but investors are finding the stock too appetizing to pass up.
Shares are down after the managed care company lowered its outlook for the year. Investors, however, are overreacting to the news.
Double-digit growth should soon resume for the plastic powerhouse.
What to do when volatility takes a rest.
Goldman and Morgan are a study in contrast.
Rail freight signals hope.
Microsoft's still a bellwether.
For the first time since it went public, Microsoft saw its revenue fall year-over-year. Tempted to buy? Don't.
Although the coffee chain's stock perked higher on stronger-than-expected results, shares should rise further.
Coca-Cola's second-quarter earnings didn't wow Wall Street. That said, the stock can add pop to your portfolio.
Positive results for the company's experimental lupus drug, Benlysta, sent shares skyrocketing by more than 200% on Monday.
This bank is rolling in dough again. Will some flow shareholders' way?
Here's one possible way to play on the quirks in quarterly reports.
Wary investors may be goaded into taking the plunge.
How hard might Obama's health-care plan hit you?
So, where's the recovery?
GE's disappointing second-quarter results suggest that investors should avoid the conglomerate's shares.